Migraine Treatment in India: A Clinical Overview
A clinical reference on migraine treatment in India: drug classes, evidence tiers, real prescribing gaps, and what determines hospital pharmacy availability.
This migraine India reference is written for the prescribing clinician or hospital administrator deciding what a formulary should carry, not a self-treatment guide. It covers drug classes, the real evidence behind each, documented gaps in Indian practice, and interactions worth flagging before a patient leaves with a prescription.
What drug classes treat an acute migraine attack?
Acute therapy uses NSAIDs and fixed-dose combination analgesics as first-line options, escalating to triptans (5-HT1B/1D receptor agonists) for attacks that don't respond, plus antiemetics for associated nausea. The right choice depends on attack severity, disability level and how quickly the patient needs relief, not a fixed ladder.
Triptans work by constricting cranial blood vessels and inhibiting the release of vasoactive peptides at trigeminal nerve terminals, addressing the underlying trigeminovascular mechanism rather than just blunting pain perception the way an NSAID does. Ergotamine and dihydroergotamine remain in use in India but carry a narrower safety margin and more contraindications than triptans, particularly around vascular disease.
A large Indian cohort review found triptans were used in only about 1.5% of migraine prescriptions, with NSAIDs and FDCs dominating actual practice even in cases where a triptan would be guideline-appropriate, and that is a real prescribing gap, not a supply one.
What preventive medications are used, and when do they start?
Preventive treatment is generally considered once a patient has two to four or more migraine days per month, or when attacks are severely disabling despite acute therapy. The major classes are tricyclic antidepressants (amitriptyline being the most studied in Indian populations), beta-blockers such as propranolol, anticonvulsants like topiramate and valproate, the calcium-channel blocker flunarizine, and, where accessible, CGRP-targeted monoclonal antibodies.
A 2024 Indian Delphi-consensus paper on amitriptyline in migraine prophylaxis found real practice variation: response is generally reassessed after roughly two weeks before adjusting therapy, and patients with coexisting depression or neuropathic pain are managed differently from those with migraine alone. That consensus exists specifically because Indian neurologists found the international literature under-specified for local practice patterns. This article does not restate dosing, since that decision sits with the treating physician case by case.
CGRP monoclonal antibodies and gepants are now framed as first-line preventive options in the 2024 American Headache Society update, a meaningfully more aggressive stance than older guidance that reserved them for treatment failures. Indian availability of this newer class remains far more limited than of the older oral preventives, which matters directly for formulary planning.
How big is the actual disease burden this treatment ladder is responding to?
Headache disorders affected roughly 3.1 billion people globally in 2021, with an estimated 1.2 billion living with migraine specifically, according to WHO and Global Burden of Disease data. Migraine ranks as one of the leading causes of years lived with disability worldwide, behind only stroke and neonatal encephalopathy among neurological and related conditions in some disability rankings.
This scale is why migraine care sits in primary care and general medicine as much as neurology in India. Most patients are never seen by a headache specialist, and the drugs a general hospital pharmacy stocks are frequently the only pharmacological access a patient gets.
Where does Indian drug information fall short of what a prescriber needs?
A peer-reviewed audit of commonly available Indian drug information sources, including CDSCO listings, found the government source only 21.77% complete on core prescribing information for migraine drugs, missing contraindications, precautions, adverse reaction detail, drug interactions and pregnancy-category data for listed triptans and ergotamine tartrate.
That gap is a genuine clinical-information problem, not a minor formatting one. A prescriber relying solely on the official listing for a triptan may not find the interaction or pregnancy data needed to prescribe safely, and has to cross-reference international sources or the product's own package insert instead.
What interactions and safety flags matter most for a hospital formulary?
Triptans should not be combined with ergotamine derivatives or within 24 hours of each other, given overlapping vasoconstrictive mechanisms and the risk of prolonged vasospasm. Triptans combined with SSRIs or SNRIs carry a recognised, if uncommon, serotonin syndrome risk that hospital pharmacists should flag at dispensing.
Amitriptyline and other TCAs interact with MAO inhibitors, carry anticholinergic burden in elderly patients, and prolong the QT interval at higher exposure, which matters in any patient already on other QT-prolonging drugs. Flunarizine carries a boxed-type caution around depression and extrapyramidal symptoms with prolonged use, which is why it's generally not a first pick for patients with a psychiatric history. Valproate carries a well-established teratogenicity risk that makes it a poor preventive choice in women of childbearing potential unless contraception is confirmed and the prescriber has documented that discussion.
What does formulary planning look like for a hospital versus a solo clinic?
Formulary planning for migraine India hospital pharmacies differs from a solo clinic mainly in referral mix. A tertiary neurology OPD needs triptans and CGRP agents on shelf; a general physician's clinic runs almost entirely on NSAIDs and the two or three standard oral preventives.
| Drug class | Typical formulary role | Stocking consideration |
|---|---|---|
| NSAIDs / FDC analgesics | First-line acute | High turnover, cheap, low storage complexity |
| Triptans | Second-line acute / moderate-severe attacks | Under-prescribed relative to guidelines; low but real demand |
| Amitriptyline | First-line oral preventive | Cheap, long shelf life, needs interaction screening at dispensing |
| Propranolol | Preventive, especially with comorbid hypertension | Common, cheap, easy to stock |
| Topiramate / valproate | Preventive, anticonvulsant class | Valproate needs a pregnancy-status flag at dispensing |
| CGRP monoclonal antibodies | Preventive, treatment-resistant cases | Cold-chain and cost make this a tertiary-centre stocking decision, not a general-ward default |
A tertiary hospital neurology OPD sees a fundamentally different mix than a general physician's clinic, and the formulary should reflect referral pattern rather than copying a generic list. Any migraine India stocking plan built on a national average rather than the hospital's own referral mix will over-stock one class and under-stock another.
Why does in-house stocking matter more than it looks like it should?
For a migraine India formulary, continuity matters as much as coverage. A patient started on a new preventive, who then can't get that exact drug filled inside the hospital, frequently doesn't return with the outside prescription filled correctly.
Attrition at that handoff point is a documented pattern in chronic-therapy adherence generally, not unique to migraine. Every prescription that walks out to an external chemist is also a break in the continuity that let the treating doctor confirm the right drug reached the right patient. For migraine specifically, where treatment is iterative and trial-based over weeks, that continuity matters more than for a one-time prescription.
A hospital's managed in-house pharmacy that reliably stocks the core preventive and acute classes keeps that iteration inside the institution instead of losing both the patient and the revenue tied to that prescription to whichever chemist happens to be near the exit. The same logic applies across hospital pharmacy operations more broadly, not just chronic-therapy classes like migraine preventives.
Sources
- 1Migraine and other headache disorders — Fact sheet — World Health Organization
- 2Information on migraine drugs in commonly available Indian drug information sources — PMC, National Institutes of Health
- 3Indian Consensus on the Role of Amitriptyline in Migraine Prophylaxis — PMC, 2024
- 4International Headache Society global practice recommendations for the acute pharmacological treatment of migraine — Cephalalgia
- 5Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050 — Global Burden of Disease Study 2021
- 6Central Drugs Standard Control Organisation — regulatory reference, Government of India
This article is for clinical-reference and informational purposes only. It is not a substitute for professional medical judgment, does not recommend a dose or treatment for any individual patient, and should not be used for self-treatment. Consult a qualified physician for any diagnosis or prescribing decision.
FAQ
Frequently asked questions
For acute attacks, NSAIDs or fixed-dose analgesic combinations are the typical first-line choice, escalating to triptans for attacks that don't respond adequately. For prevention, amitriptyline and propranolol remain the most commonly used first-line oral options in Indian practice.
Guidelines generally suggest considering preventive therapy once a patient has two to four or more migraine days a month, or when attacks cause significant disability despite acute treatment. The exact threshold is a clinical judgment made by the treating physician.
Triptans are approved and available in India, but real-world data shows they are used in only a small fraction of migraine prescriptions compared to NSAIDs and combination analgesics, reflecting a documented gap between guideline recommendations and everyday prescribing.
Yes. CGRP-targeted monoclonal antibodies block a specific neuropeptide implicated in migraine pathophysiology, rather than acting broadly like tricyclics or beta-blockers. They're a newer preventive class with far more limited availability and higher cost in Indian hospitals than established oral options.
Amitriptyline interacts with MAO inhibitors and other serotonergic drugs, carries anticholinergic and QT-prolongation risk, and needs dose and interaction review in elderly patients or those on multiple other medications. That decision sits with the treating physician, not a fixed rule.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.